Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes

[21] He J(1997)The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 776-1145

[22] Appel LJ(2021)Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11) Diabetes Care 44 2242-R880

[23] Cutler JA(2016)Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program Diabetes Metab Res Rev 32 121-1552

[24] Havas S(2021)Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD-11 Diabetes Obes Metab 23 1117-2391

[25] Kotchen TA(2019)Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet 394 R874-405

[26] Reboldi G(2020)2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol 76 194-139

[27] Gentile G(2008)Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans Am J Physiol Regul Integr Comp Physiol 295 1546-158

[28] Angeli F(2021)Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND Cardiovasc Diabetol 20 2389-2946

[29] Ambrosio G(2020)Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial Diabetes Care 43 8-523

[30] Mancia G(2015)Aging and pulse pressure widening: the inseparable duo? J Hypertens 33 1-1007

[21] He J(1997)The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 776-1145

[22] Appel LJ(2021)Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11) Diabetes Care 44 2242-R880

[23] Cutler JA(2016)Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program Diabetes Metab Res Rev 32 121-1552

[24] Havas S(2021)Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD-11 Diabetes Obes Metab 23 1117-2391

[25] Kotchen TA(2019)Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet 394 R874-405

[26] Reboldi G(2020)2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol 76 194-139

[27] Gentile G(2008)Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans Am J Physiol Regul Integr Comp Physiol 295 1546-158

[28] Angeli F(2021)Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND Cardiovasc Diabetol 20 2389-2946

[29] Ambrosio G(2020)Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial Diabetes Care 43 8-523

[30] Mancia G(2015)Aging and pulse pressure widening: the inseparable duo? J Hypertens 33 1-1007